Orouba Almilaji, Gwilym Webb, Alec Maynard, Thomas P Chapman, Brian S F Shine, Antony J Ellis, John Hebden, Sharon Docherty, Elizabeth J Williams, Jonathon Snook
{"title":"缺铁性贫血胃肠道恶性肿瘤多变量风险预测模型的广泛外部验证。","authors":"Orouba Almilaji, Gwilym Webb, Alec Maynard, Thomas P Chapman, Brian S F Shine, Antony J Ellis, John Hebden, Sharon Docherty, Elizabeth J Williams, Jonathon Snook","doi":"10.1186/s41512-021-00112-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Using two large datasets from Dorset, we previously reported an internally validated multivariable risk model for predicting the risk of GI malignancy in IDA-the IDIOM score. The aim of this retrospective observational study was to validate the IDIOM model using two independent external datasets.</p><p><strong>Methods: </strong>The external validation datasets were collected, in a secondary care setting, by different investigators from cohorts in Oxford and Sheffield derived under different circumstances, comprising 1117 and 474 patients with confirmed IDA respectively. The data were anonymised prior to analysis. The predictive performance of the original model was evaluated by estimating measures of calibration, discrimination and clinical utility using the validation datasets.</p><p><strong>Results: </strong>The discrimination of the original model using the external validation data was 70% (95% CI 65, 75) for the Oxford dataset and 70% (95% CI 61, 79) for the Sheffield dataset. The analysis of mean, weak, flexible and across the risk groups' calibration showed no tendency for under or over-estimated risks in the combined validation data. Decision curve analysis demonstrated the clinical value of the IDIOM model with a net benefit that is higher than 'investigate all' and 'investigate no-one' strategies up to a threshold of 18% in the combined validation data, using a risk cut-off of around 1.2% to categorise patients into the very low risk group showed that none of the patients stratified in this risk group proved to have GI cancer on investigation in the validation datasets.</p><p><strong>Conclusion: </strong>This external validation exercise has shown promising results for the IDIOM model in predicting the risk of underlying GI malignancy in independent IDA datasets collected in different clinical settings.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":" ","pages":"23"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672477/pdf/","citationCount":"0","resultStr":"{\"title\":\"Broad external validation of a multivariable risk prediction model for gastrointestinal malignancy in iron deficiency anaemia.\",\"authors\":\"Orouba Almilaji, Gwilym Webb, Alec Maynard, Thomas P Chapman, Brian S F Shine, Antony J Ellis, John Hebden, Sharon Docherty, Elizabeth J Williams, Jonathon Snook\",\"doi\":\"10.1186/s41512-021-00112-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Using two large datasets from Dorset, we previously reported an internally validated multivariable risk model for predicting the risk of GI malignancy in IDA-the IDIOM score. The aim of this retrospective observational study was to validate the IDIOM model using two independent external datasets.</p><p><strong>Methods: </strong>The external validation datasets were collected, in a secondary care setting, by different investigators from cohorts in Oxford and Sheffield derived under different circumstances, comprising 1117 and 474 patients with confirmed IDA respectively. The data were anonymised prior to analysis. The predictive performance of the original model was evaluated by estimating measures of calibration, discrimination and clinical utility using the validation datasets.</p><p><strong>Results: </strong>The discrimination of the original model using the external validation data was 70% (95% CI 65, 75) for the Oxford dataset and 70% (95% CI 61, 79) for the Sheffield dataset. The analysis of mean, weak, flexible and across the risk groups' calibration showed no tendency for under or over-estimated risks in the combined validation data. Decision curve analysis demonstrated the clinical value of the IDIOM model with a net benefit that is higher than 'investigate all' and 'investigate no-one' strategies up to a threshold of 18% in the combined validation data, using a risk cut-off of around 1.2% to categorise patients into the very low risk group showed that none of the patients stratified in this risk group proved to have GI cancer on investigation in the validation datasets.</p><p><strong>Conclusion: </strong>This external validation exercise has shown promising results for the IDIOM model in predicting the risk of underlying GI malignancy in independent IDA datasets collected in different clinical settings.</p>\",\"PeriodicalId\":72800,\"journal\":{\"name\":\"Diagnostic and prognostic research\",\"volume\":\" \",\"pages\":\"23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672477/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diagnostic and prognostic research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41512-021-00112-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic and prognostic research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41512-021-00112-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:我们曾利用两个来自多塞特郡的大型数据集,报告了一个经过内部验证的多变量风险模型--IDIOM评分,用于预测IDA消化道恶性肿瘤的风险。这项回顾性观察研究旨在利用两个独立的外部数据集验证 IDIOM 模型:外部验证数据集由不同的研究者在二级医疗机构收集,分别来自牛津和谢菲尔德在不同情况下产生的队列,包括 1117 名和 474 名确诊 IDA 患者。数据在分析前已匿名。通过使用验证数据集估算校准度、辨别度和临床实用性,对原始模型的预测性能进行了评估:使用外部验证数据,牛津数据集的原始模型辨别率为 70% (95% CI 65, 75),谢菲尔德数据集的原始模型辨别率为 70% (95% CI 61, 79)。对平均、弱、灵活和跨风险组校准的分析表明,在综合验证数据中没有低估或高估风险的趋势。决策曲线分析表明了 IDIOM 模型的临床价值,其净收益高于 "全部检查 "和 "不检查任何人 "策略,在综合验证数据中的阈值为 18%,使用约 1.2% 的风险临界值将患者划分为极低风险组,结果显示,在验证数据集中,该风险组中的分层患者在检查时均未证实患有消化道癌症:这项外部验证工作表明,在不同临床环境下收集的独立 IDA 数据集中,IDIOM 模型在预测潜在消化道恶性肿瘤风险方面具有良好的效果。
Broad external validation of a multivariable risk prediction model for gastrointestinal malignancy in iron deficiency anaemia.
Background: Using two large datasets from Dorset, we previously reported an internally validated multivariable risk model for predicting the risk of GI malignancy in IDA-the IDIOM score. The aim of this retrospective observational study was to validate the IDIOM model using two independent external datasets.
Methods: The external validation datasets were collected, in a secondary care setting, by different investigators from cohorts in Oxford and Sheffield derived under different circumstances, comprising 1117 and 474 patients with confirmed IDA respectively. The data were anonymised prior to analysis. The predictive performance of the original model was evaluated by estimating measures of calibration, discrimination and clinical utility using the validation datasets.
Results: The discrimination of the original model using the external validation data was 70% (95% CI 65, 75) for the Oxford dataset and 70% (95% CI 61, 79) for the Sheffield dataset. The analysis of mean, weak, flexible and across the risk groups' calibration showed no tendency for under or over-estimated risks in the combined validation data. Decision curve analysis demonstrated the clinical value of the IDIOM model with a net benefit that is higher than 'investigate all' and 'investigate no-one' strategies up to a threshold of 18% in the combined validation data, using a risk cut-off of around 1.2% to categorise patients into the very low risk group showed that none of the patients stratified in this risk group proved to have GI cancer on investigation in the validation datasets.
Conclusion: This external validation exercise has shown promising results for the IDIOM model in predicting the risk of underlying GI malignancy in independent IDA datasets collected in different clinical settings.